Interstitial Pneumonitis Related to Granulocyte Colony-Stimulating Factor Administration Following Chemotherapy for Elderly Patients with Non-Hodgkin's Lymphoma

Internal Medicine

Volumn 36, Issue 5, 1997, Pages 360-364

  Hasegawa, Yuichi ^a   Ninomiya, Haruhiko ^a   Kamoshita, Masaharu ^a   Ohtani, Koji ^a   Kobayashi, Toshitaka ^a   Kojima, Hiroshi ^a   Nagasawa, Toshiro ^a   Abe, Tsukasa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cytokines; Granulocyte colony stimulating factor (G CSF); Lung damage

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; LEUKOCYTE ELASTASE; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

AGED; ARTICLE; BLOOD GAS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; NEUTROPHILIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; RISK FACTOR; SCINTIGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX RADIOGRAPHY;

EID: 0030797723     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.36.360     Document Type: Article

References (27)

1. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 82: 1526, 1985.
2. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319: 415, 1986.
3. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232: 61, 1986.
4. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 31: 1860, 1971.
5. Suchi T, Tajima K, Nanba K, et al. Some problems on the histopathological diagnosis of non-Hodgkin's malignant lymphoma. A proposal of a new type. Acta Pathol Jpn 29: 755, 1979.
6. Shimizu M, Miura M, Kitahara M, Katayama I. Non-Hodgkin's lymphomas. Analysis of 109 Japanese cases with the use of LSGJ classification. Am J Pathol 106: 30, 1982.
7. Mitsuhashi S, Ninomiya H, Shibuya A. et al. Effect of THP-CVP regimen for elderly patients with malignant lymphoma. Rinsho Ketsueki 34: 1532, 1993 (in Japanese with English abstract).
8. Iki S, Yoshinaga K, Ohbayashi Y, Urabe A. Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF-clinical attention. Ann Hematol 66: 217, 1993 (letter).
9. Okubo Y, Nakazawa K. Recombinant G-CSF and interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin's lymphoma. Rinsho Ketsueki 34: 473, 1993 (in Japanese with English abstract).
10. Motomura S, Fujisawa S, Fujimaki K, Mohri H, Okubo T. Interstitial pneumonia induced by combination therapy with low-dose cytarabine and granulocyte colony-stimulating factor. Am J Hematol 49: 364, 1995 (letter).
11. Ibayashi Y, Ohyama H, Hashimoto Y, et al. A case report of interstitial pneumonia caused by granulocyte colony-stimulating factor. No Shinkei Geka 22: 169, 1994 (in Japanese with English abstract).
12. Niitsu N, Shikoshi K, Nakayama M, Umeda M: Three patients with nonHodgkin's lymphoma contracting interstitial pneumonia upon G-CSF administration during COP-BLAM treatment. Biotherapy 9: 1177, 1995 (in Japanese with English abstract).
13. Katoh M, Shikoshi K, Takada M, Umeda M, et al. Development of interstitial pneumonitis during treatment with granulocyte colony-stimulating factor. Ann Hematol 67: 201, 1993 (letter).
14. Dirix LY, Schrijvers D, Druwe P, Van Den Brande J, Verhocven D. Van Oosterom AT: Pulmonary toxicity and bleomycin. Lancet 344: 56, 1994 (letter; see comments).
15. Matthews JH. Pulmonary toxicity of AB VD chemotherapy und G-CSF in Hodgkin's disease: possible synergy. Lancet 342: 988, 1993 (letter; see comments).
16. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133: 321, 1986.
17. Burger RM, Peisach J, Horwitz SB. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 256: 11636, 1981.
18. Toledo CH, Ross WE, Hood CI, Block ER. Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep 66: 359, 1982.
19. Lindemann A, Hermann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74: 2644, 1989.
20. Balazovich KJ, Almeida HI, Boxer LA. Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms. J Lab Clin Med 118: 576, 1991.
21. Yuan L, Inoue S, Saito Y, Nakajima O. An evaluation of the effects of cytokines on intracellular oxidative production in normal neutrophils by flow cytometry. Exp Cell Res 209: 375, 1993.
22. de Haas M, Kerst JM, van der School CE, et al. Granulocyte colonystimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 84: 3885, 1994.
23. Iijima S, Tsuji T, Sugita M, Yamada N, Satoh T, Kubo T. Leukocyte activity and occurrence of tissue injury by G-CSF. Nippon Sanka Fujinka Gakkai Zasshi 45: 213, 1993 (in Japanese with English abstract).
24. Mendoza JF, Caceres JR, Santiago E, et al. Evidence that G-CSF is a libroblasl growth factor that induces granulocytes to increase phagocytosis and to present a mature morphology, and that macrophages secrete 45-kD molecules with these activities as well as with G-CSF-like activity. Exp Hematol 18: 903, 1990.
25. Jensen JC, Pogrebniak HW, Pass HI, et al. Role of tumor necrosis factor in oxygen toxicity. J Appl Physiol 72: 1902, 1992.
26. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cuchectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170: 655, 1989.
27. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 140: 2994, 1988.